Atossa Q2 2026: OpEx $8.7M, R&D $4.9M; raises up to $16.5M from offering

ATOSSA THERAPEUTICS, INC.

2026-Q2 EPS reported -$2.06

Total operating expenses $8.7M in Q2 2026, down $0.3M from $9.0M in Q2 2025.
R&D expenses $4.9M in Q2 2026, down 11% YoY on lower preclinical spend.
G&A expenses $3.8M, up 7% YoY, driven by higher legal fees from settled patent litigation.
Raised $4.5M upfront plus up to $12M from Series A/B warrant exercises to fund (Z)-endoxifen.
Presented (Z)-endoxifen data at ASCO/AACR; EVANGELINE Phase 2 enrollment completed as of June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.